The pursuit of market outperformance leads investors to the practice of hand-picking stocks. Skillful choices can be a catalyst for significant wealth enhancement.
The closing price of Halozyme Therapeutics Inc (NASDAQ: HALO) was $74.93 for the day, up 2.08% from the previous closing price of $73.4. In other words, the price has increased by $2.08 from its previous closing price. On the day, 1.89 million shares were traded. HALO stock price reached its highest trading level at $74.96 during the session, while it also had its lowest trading level at $72.39.
Ratios:
Our analysis of HALO’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 15.99 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 16.21. For the most recent quarter (mrq), Quick Ratio is recorded 7.01 and its Current Ratio is at 8.36. In the meantime, Its Debt-to-Equity ratio is 4.54 whereas as Long-Term Debt/Eq ratio is at 4.54.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Sep 03 ’25 when Torley Helen sold 20,000 shares for $74.44 per share. The transaction valued at 1,488,726 led to the insider holds 733,719 shares of the business.
Torley Helen sold 20,000 shares of HALO for $1,480,772 on Sep 04 ’25. The PRESIDENT AND CEO now owns 733,719 shares after completing the transaction at $74.04 per share. On Sep 02 ’25, another insider, Torley Helen, who serves as the PRESIDENT AND CEO of the company, sold 20,000 shares for $73.76 each. As a result, the insider received 1,475,128 and left with 733,719 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, HALO now has a Market Capitalization of 8764262400 and an Enterprise Value of 9754155008. As of this moment, Halozyme’s Price-to-Earnings (P/E) ratio for their current fiscal year is 17.12, and their Forward P/E ratio for the next fiscal year is 9.41. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.53. For the stock, the TTM Price-to-Sale (P/S) ratio is 7.44 while its Price-to-Book (P/B) ratio in mrq is 26.49. Its current Enterprise Value per Revenue stands at 8.276 whereas that against EBITDA is 12.858.
Stock Price History:
The Beta on a monthly basis for HALO is 1.17, which has changed by 0.2648548 over the last 52 weeks, in comparison to a change of 0.18469036 over the same period for the S&P500. Over the past 52 weeks, HALO has reached a high of $75.46, while it has fallen to a 52-week low of $42.01. The 50-Day Moving Average of the stock is 20.17%, while the 200-Day Moving Average is calculated to be 30.91%.
Shares Statistics:
HALO traded an average of 2.19M shares per day over the past three months and 2173220 shares per day over the past ten days. A total of 117.62M shares are outstanding, with a floating share count of 115.68M. Insiders hold about 1.11% of the company’s shares, while institutions hold 100.69% stake in the company. Shares short for HALO as of 1755216000 were 10571710 with a Short Ratio of 4.83, compared to 1752537600 on 9602474. Therefore, it implies a Short% of Shares Outstanding of 10571710 and a Short% of Float of 12.620000000000001.
Earnings Estimates
The stock of Halozyme Therapeutics Inc (HALO) is currently drawing attention from 7.0 analysts actively involved in the ongoing evaluation and rating process.The consensus estimate for the next quarter is $1.85, with high estimates of $1.99 and low estimates of $1.65.
Analysts are recommending an EPS of between $6.31 and $5.38 for the fiscal current year, implying an average EPS of $6.05. EPS for the following year is $7.85, with 6.0 analysts recommending between $8.5 and $7.17.
Revenue Estimates
It is expected that $90B in revenue will be generated in the current quarter, according to 7 analysts. It ranges from a high estimate of $350M to a low estimate of $331.4M. As of the current estimate, Halozyme Therapeutics Inc’s year-ago sales were $290.08MFor the next quarter, 7 analysts are estimating revenue of $392.21M. There is a high estimate of $405.7M for the next quarter, whereas the lowest estimate is $378.4M.
A total of 9 analysts have provided revenue estimates for HALO’s current fiscal year. The highest revenue estimate was $1.34B, while the lowest revenue estimate was $1.31B, resulting in an average revenue estimate of $1.32B. In the same quarter a year ago, actual revenue was $1.02BBased on 8 analysts’ estimates, the company’s revenue will be $1.63B in the next fiscal year. The high estimate is $1.69B and the low estimate is $1.54B.
